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Abstract
Objective—MicroRNA (miRNA) are recognized as important regulators of a variety of
fundamental biologic processes. Previously, we described increased expression of miR-155 and
miR-146a in rheumatoid arthritis (RA) and showed a repressive effect of miR-155 on matrix
metalloproteinase (MMP) expression in RA synovial fibroblasts (RASFs). The present study was
undertaken to examine alterations in expression of miR-203 in RASFs and analyze its role in
fibroblast activation.
Methods—Differentially expressed miRNA in RASFs versus osteoarthritis synovial fibroblasts
(OASFs) were identified by real-time polymerase chain reaction (PCR)–based screening of 260
individual miRNA. Transfection of miR-203 precursor was used to analyze the function of
miR-203 in RASFs. Levels of interleukin-6 (IL-6) and MMPs were measured by real-time PCR
and enzyme-linked immunosorbent assay. RASFs were stimulated with IL-1β, tumor necrosis
factor α (TNFα), lipopolysaccharide (LPS), and 5-azacytidine (5-azaC). Activity of IκB kinase 2
was inhibited with SC-514.
Results—Expression of miR-203 was higher in RASFs than in OASFs or fibroblasts from
healthy donors. Levels of miR-203 did not change upon stimulation with IL-1β, TNFα, or LPS;
however, DNA demethylation with 5-azaC increased the expression of miR-203. Enforced
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expression of miR-203 led to significantly increased levels of MMP-1 and IL-6. Induction of IL-6
by miR-203 overexpression was inhibited by blocking of the NF-κB pathway. Basal expression
levels of IL-6 correlated with basal expression levels of miR-203.
Conclusion—The current results demonstrate methylation-dependent regulation of miR-203
expression in RASFs. Importantly, they also show that elevated levels of miR-203 lead to
increased secretion of MMP-1 and IL-6 via the NF-κB pathway and thereby contribute to the
activated phenotype of synovial fibroblasts in RA.
MicroRNA (miR) are ~21-nucleotide-long RNA molecules that regulate the expression of
target genes by translational inhibition or messenger RNA (mRNA) degradation (1-3).
Expression of a distinct protein can be changed by several different miRNA. In turn, one
miRNA can modulate the expression of hundreds of different targets (4). In the last few
years it has become clear that miRNA are indispensible for the proper functioning of the
mechanisms regulating cell cycle and cellular death, cellular differentiation, and immunity
(5,6). Thus, it is not surprising that dysregulated expression of miRNA is being found in an
increasing number of pathologic conditions, such as cancer, cardiovascular disease,
infectious disease, and autoimmunity (7,8).
Some up-regulated and down-regulated miRNA have also been identified in rheumatoid
arthritis (RA). In particular, we and others have found increased expression of miR-155 in
synovial fibroblasts, peripheral blood mononuclear cells (PBMCs), synovial tissue, and
synovial fluid monocytes of RA patients (9,10). Of note, enforced in vitro expression of
miR-155 led to decreased levels of matrix metalloproteinase 3 (MMP-3) and blocked the
induction of MMP-1 and MMP-3 after stimulation with proinflammatory cytokines and
Toll-like receptor (TLR) ligands (10). These data show that MMP-1 and MMP-3 are indirect
targets of miR-155, but also reveal a more complex picture of miRNA regulation in RA,
with increased expression of counterregulatory mechanisms. In contrast to miR-155,
miR-124 was recently reported to be down-regulated in RA synovial fibroblasts (RASFs)
(11). In vitro overexpression of miR-124 by transfection with its precursor (pre–miR-124)
lowered the production of cyclin-dependent kinase 2 and monocyte chemoattractant protein
1. Another microRNA, miR-146, was found to be elevated in RA synovial tissue, synovial
fibroblasts, and PBMCs in 3 independent studies including one from our group (9,10,12).
However, functional consequences of miR-146 overexpression and direct targets of miR-146
that are affected in RA have not been identified to date.
To further elucidate the nature of miRNA dys-regulation in RA, in the current study we
compared the miRNA expression profiles of synovial fibroblasts from RA patients and
osteoarthritis (OA) patients and found miR-203 to be up-regulated in RA. We further
studied its regulation by proinflammatory molecules and epigenetic mechanisms, and found
evidence to support previous reports of the regulation of miR-203 expression via DNA
methylation (13-16). Finally, we found that overexpression of miR-203 results in increased
secretion of interleukin-6 (IL-6) and MMP-1 by RASFs, identifying miR-203 as a
proinflammatory and joint-destructive factor in RA.
PATIENTS AND METHODS
Tissue specimens and cells
Synovial tissue was obtained from RA patients, OA patients, and joint trauma patients
(healthy control specimens) undergoing joint replacement surgery in the Schulthess Clinic
Zurich. Informed consent was obtained from all patients, and RA patients fulfilled the
American College of Rheumatology criteria for classification of the disease (17). For tissue
analysis, tissue was snap-frozen and stored at −80°C. For cell culture, tissue was digested
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and synovial fibroblasts grown as previously described (10). Synovial tissue samples from
patients with very early RA were obtained from patients presenting to a rapid-access early
arthritis clinic who had synovitis of at least 1 joint and a symptom duration of <3 months (n
= 5). Consenting patients underwent ultrasound-guided biopsy of a knee or ankle joint at
baseline, with synovial fibroblasts grown from a minimum of 8 tissue biopsy specimens per
joint to account for heterogeneity. Samples were used from patients who fulfilled the
American College of Rheumatology criteria for the classification of RA within the
subsequent 18 months.
Reagents
Tumor necrosis factor α (TNFα; R&D Systems) was used at 10 ng/ml, interleukin-1β
(IL-1β; R&D Systems) was used at 1 ng/ml, and lipopolysaccharide (LPS) from Escherichia
coli (List Biological Laboratories) was used at 100 ng/ml; 5-azacytidine (5-azaC; Sigma-
Aldrich) was added to cell culture medium at 1 μM every day for 1 week. Activity of IκB
kinase 2 (IKK-2) was inhibited with the IKK-2 inhibitor SC-514 (Sigma-Aldrich). SC-514
was added at a concentration of 50 nM 12 hours after transfection, and supernatants were
collected after a further 12 hours.
Real-time polymerase chain reaction (PCR)
For screening of miRNA expression in RASFs and OASFs, a human miRNA panel
(Ambion–Applied Biosystems) consisting of 260 assays for individual miRNA was applied.
For miRNA analysis, RNA was isolated from fibroblasts and synovial tissue with the
mirVana Isolation Kit (Ambion–Applied Biosystems). RNA (10 ng) was reverse-transcribed
using MultiScribe reverse transcriptase (RT), RT buffer, dNTPs, RNase inhibitor, and miR-
specific primers in the GeneAmp 9700 PCR system (all from Applied Biosystems). The
complementary DNA (cDNA) obtained was applied in real-time PCR using miR-specific
TaqMan primers (Applied Biosystems). For relative quantification, expression of let-7a was
used as an endogenous control. In the analysis of the expression of IL-6 and MMPs, RNA
was isolated with the RNeasy Mini kit (Qiagen) including DNA digestion with RNase-free
DNA. Total RNA was reverse-transcribed using MultiScribe RT, RT buffer, dNTPs, RNase
inhibitor, and random hexamers (all from Applied Biosystems). TaqMan assays were used
for the detection of mRNA for MMPs and the endogenous control gene 18S, and SYBR
Green assays for the detection of IL-6 mRNA. For all reactions, the Ct method was used for
calculations, as previously described (10).
Overexpression of miR-203
Lipofectamine 2000 was used, according to the protocol recommended by the manufacturer
(Gibco Invitrogen), to transfect RASFs with 100 nM synthetic pre–miR-203 or pre-miR
negative control (Pre-miR miRNA Precursor Molecules and Pre-miR miRNA Precursor
Negative Controls; both from Ambion–Applied Biosystems). Pre-miR miRNA Precursor
Molecules are chemically modified double-stranded RNA molecules that mimic endogenous
mature miR when transfected into cells. Pre-miR miRNA Precursor Negative Controls are
validated negative control, random sequence molecules that do not produce an effect on miR
function.
IL-6 and MMP-1 protein measurements
Levels of IL-6 and MMP-1 were measured in cell supernatants, by enzyme-linked
immunosorbent assay (ELISA). For IL-6, an OptEIA kit was used according to the
instructions of the manufacturer (BD PharMingen). For MMP-1, the SensoLyte ELISA kit
(AnaSpec) was used.
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In silico promoter analysis and prediction algorithms
Prediction of CpG islands in miR-203 and let-7a genes was done by in silico promoter
analysis with MethPrimer (18). For the prediction of miR-203 targets, algorithms from the
following software packages were used: TargetScan human 5.1 (19), MicroCosm Targets
version 5, and PicTar (20).
Statistical analysis
Mean ± SEM values were calculated, and Wilcoxon’s matched pairs test or the Mann-
Whitney U test was used for statistical comparisons. Where noted, Bonferroni correction for
multiple testing was applied. Fold changes in scores were compared to a baseline value set
at 1. Spearman’s rank correlation was used for correlating miR-203 and IL-6 levels. P values
less than 0.05 were considered significant. GraphPad Prism 5.01 was used for statistical
analysis.
RESULTS
Increased basal expression of miR-203 in synovial fibroblasts from RA patients
To investigate for differentially expressed miR in RA and OA synovial fibroblasts, we
analyzed the expression of 260 miR in synovial fibroblasts from 3 RA patients and 3 OA
patients, by real-time PCR. In that analysis, miR-203 emerged among the miR that were
most differentially expressed between RASFs and OASFs. Levels of miR-203 were 2.8-fold
higher in cultured RASFs than in OASFs and 8.9-fold higher than in synovial fibroblasts
from healthy controls (Figure 1A). Also, expression of miR-203 in OASFs was 3.2-fold
higher than in healthy controls. Interestingly, the expression of miR-203 in synovial
fibroblasts from patients with very early RA (<3 months since the onset of symptoms) was
highly variable, with some patients expressing amounts of miR-203 similar to those
expressed by patients with longstanding disease (mean ± SEM 16 ± 5 years) and others
exhibiting levels similar to those in healthy controls or OA patients. Analysis of miR-203
levels in RASFs according to therapeutic regimen did not reveal any influence of medication
on constitutive expression of miR-203 in cultured cells (Table 1). Measurements of miR-203
in synovial tissue showed no difference between RA and OA patients (Figure 1B).
Regulation of miR-203 expression by epigenetic mechanisms
We next studied the regulation of miR-203 expression in synovial fibroblasts stimulated
with the proinflammatory cytokines TNFα and IL-1β and the TLR-4 ligand LPS. None of
these stimuli had any influence on the expression of miR-203 in RASFs (Figure 2A). Based
on previous studies performed at our laboratory that showed that DNA in RASFs is
generally hypomethylated (21) and published results from other groups suggesting
modulation of miR-203 expression by epigenetic mechanisms (13), we hypothesized that the
level of miR-203 in synovial fibroblasts might be regulated via hypomethylation of its
promoter region. Additionally, in silico analysis of the upstream region of the miR-203
transcription initiation site predicted a CpG island in this region, providing evidence of
transcription regulation by methylation of this gene. In contrast, the promoter of the let-7a
gene showed a low CpG percentage and no CpG island (Figure 2B). To test the hypothesis,
we stimulated normal synovial fibroblasts (n = 2) with the demethylating drug 5-azaC for 5
days and indeed found that expression of miR-203 was higher in demethylated than in
untreated synovial fibroblasts, while the expression of let-7a remained unchanged (Figure
2C). When the fold increase of miR-203 expression relative to let-7a expression in these 2
samples was calculated using the Ct method, increases of 306-fold and 27-fold, respectively,
were observed after 5-azaC treatment.
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Increased expression of miR-203 results in higher levels of MMP-1 in RASFs
To elucidate the functional consequences of increased miR-203 expression in RASFs, we
used miR-203–specific precursors for gain-of-function experiments. To ascertain whether
overexpression of miR-203 has any effect on the expression of MMPs, we measured mRNA
for MMP-1, MMP-3, MMP-9, and MMP-13 in pre–miR-203– and control pre-miR–
transfected RASFs. After 24 and 48 hours, MMP-1 transcripts were increased by 2-fold
(Figure 3A). RASFs transfected with pre–miR-203 also produced significantly more MMP-1
protein than control pre-miR–transfected RASFs (Figure 3B). Specifically, mean ± SEM
levels of MMP-1 increased from 2,851 ± 714 pg/ml to 4,982 ± 1,027 pg/ml (69 ± 10%) after
pre-miR–203 transfection. Levels of MMP-3, MMP-9, and MMP-13 transcripts were not
significantly influenced by pre–miR-203 transfection (Figure 3C). Even though a trend
toward higher MMP-13 levels was seen after pre–miR-203 transfection, the changes were
not consistent and therefore not statistically significant.
IL-6 regulation by miR-203 via the NF-κB pathway
After transfection with pre–miR-203, a gradual increase in IL-6 mRNA levels was observed
over time, and 48 hours after transfection, IL-6 mRNA levels were significantly increased in
pre–miR-203–transfected RASFs compared with negative control–transfected cells (mean ±
SEM 2.4 ± 0.3–fold increase) (Figure 4A). In addition, IL-6 protein levels were significantly
increased, from 617 ± 132 pg/ml in control-transfected to 901 ± 162 pg/ml in pre-miR-203–
transfected RASFs (58 ± 13% increase) (Figure 4B). Consistent with these findings, basal
expression levels of IL-6 mRNA in synovial fibroblasts strongly correlated with basal
miR-203 levels (rs = 0.76, P = 0.007) (Figure 4C).
Since IL-6 is obviously not a direct target of miR-203, we sought upstream pathways that
are affected by miR-203 overexpression. Previous studies have shown that RASFs
spontaneously produce more IL-6 than OASFs (22,23). This constitutive transcription of
IL-6 has been ascribed to the autonomous activation of NF-κB (22,24). Based on this
knowledge, we used an IKK-2 inhibitor to determine whether up-regulation of IL-6 via
miR-203 was dependent on the NF-κB pathway. Figure 4D shows that IKK-2 inhibition
totally blocked pre–miR-203–induced IL-6 production. In accordance with the above-
mentioned findings, inhibition of NF-κB also significantly blocked the spontaneous
production of IL-6 in RASFs.
Expression of NF-κB pathway modulator genes after overexpression of miR-203
Based on the above data, we speculated that the direct target of miR-203 might be an
inhibitor of the NF-κB pathway. Using different miRNA target gene prediction algorithms
(Pic-Tar, TargetScan, and MicroCosm Targets), we browsed the predicted targets of
miR-203 for modulators of the NF-κB pathway. In this list we found 9 genes whose down-
regulation by miR-203 might lead to increased activity of NF-κB. The predicted targets
included the members of the IκB family nuclear factor of κ light polypeptide gene enhancer
in B cells inhibitor and NF-κB p100, as well as NF-κB–repressing factor, and Tax1-binding
protein 1, TNFα-induced protein 3, and ring finger protein 11, which form an NF-κB
inhibitory complex. We also analyzed suppressor of cytokine signaling 3 (SOCS-3) and
SOCS-6 and methyl CpG binding protein 2. Transcripts of each of these genes were
measured (n = 3) 12 hours, 24 hours, 48 hours, and 72 hours after pre–miR-203 transfection.
However, no down-regulation of the expression of any of the measured predicted targets
was seen (Figure 5).
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DISCUSSION
In the current study we showed that the basal expression of miR-203 is increased in RASFs
compared to OASFs and that overexpression of miR-203 in these cells leads to increased
production of MMP-1 and IL-6. By demonstrating this, we identified miR-203 as another
miRNA with altered expression in RASFs.
Pathologic expression of miR-203 has mainly been identified in various malignant tumors,
where its expression levels are mostly found to be higher than in normal tissue (25-28). In
some malignancies, however, miR-203 levels are down-regulated (14,16,29), indicating that
it can also function as a tumor suppressor. In particular in hematopoietic malignancies,
restoration of miR-203 leads to decreased expression of the oncoprotein BCR-ABL1 (13). In
accordance with our data, studies of cancer cells have also shown that the expression of
miR-203 is regulated by CpG methylation and can be modulated by demethylating agents
(13-16).
Apart from tumor pathology, miR-203 has been shown to play an important role in
keratinocyte differentiation in the skin and was found to be highly expressed in psoriatic
skin plaques (30,31). Most interestingly, cultured dermal cell suspensions from lesional
psoriatic skin spontaneously produce more IL-6 protein than do nonlesional psoriatic or
healthy cells (32). Our findings, together with reports of increased miR-203 expression in
psoriasis (32), suggest that the link between IL-6 and miR-203 might also apply in other
chronic inflammatory diseases.
In earlier studies we demonstrated for the first time that expression of miR-155 and
miR-146a is altered in RA synovium and synovial fibroblasts and provided evidence of a
functional role of miR-155 as a modulator of MMP-3 and MMP-1 expression in RASFs
(10). Recently, published data by another group revealed that miR-124a is down-regulated
in RASFs and contributes to the regulation of cell proliferation and the production of
monocyte chemoattractant protein 1 (11). Based on these reports a complex picture of
altered expression of miRNA in RASFs emerges, and its functional relevance to the
development of the disease phenotype becomes evident.
Previously, our group suggested that the longstanding, inflammatory milieu in RA leads to
epigenetic changes in synovial fibroblasts and showed that DNA in RASFs is globally
hypomethylated (21). In the present study, we demonstrated that demethylating treatment of
synovial fibroblasts leads to increased expression of miR-203. Therefore, we propose that
the constitutively high production of miR-203 in RASFs may be due to changes in
epigenetic modifications in the promoter of the miR-203 gene. The variable levels of
miR-203 that we measured in RASFs from patients with symptoms of very recent onset (<3
months) support the hypothesis that this epigenetic switch is turned on during the
development of the disease, which may eventually lead to the imprinted activated phenotype
of synovial fibroblasts seen in RA (33). Interestingly, the fact that 2 of the patients with
early RA already exhibited levels of miR-203 as high as those in patients with established
RA suggests that miR-203 is involved in the pathogenesis of the disease in its very early
stage. It must be stressed, however, that further in vivo experiments are needed to confirm
this hypothesis.
The finding that expression of miR-203 was not increased in the synovial tissue of RA
patients can be explained by the pronounced heterogeneity and vast interindividual
differences in the cellular composition of inflamed synovial tissue. If increased miR-203
levels are a specific feature of hypomethylated synovial fibroblasts, the high numbers of
inflammatory and vascular cells in synovial tissue lysates might conceal differences between
the fibroblast populations.
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IL-6 is one of the major proinflammatory cytokines present in abundance in rheumatoid
joints, and recently, therapeutic regimens targeting IL-6 have been successfully introduced
into clinical practice (34,35). Of interest, resident cells of the joint, i.e., synovial fibroblasts,
are recognized as a major source of this cytokine, and even more interestingly, RASFs in
vitro are characterized by higher spontaneous production of IL-6 as compared to OASFs
(22,23). To better understand the contribution of miR-203 to the modulation of IL-6 levels
in RASFs, knowing that NF-κB is the major transcription factor driving basal expression of
IL-6 in synovial fibroblasts, we analyzed the influence of miR-203 on the NF-κB signaling
pathway and were able to clearly show that miR-203 is dependent on NF-κB activity to
modulate IL-6 levels. Therefore, our study identifies miR-203 as a novel endogenously
altered modulator of IL-6 expression in RASFs, which is upstream of NF-κB. However,
using miR target prediction algorithms, we could not identify the direct miR-203 target
involved in this mechanism.
In recent years it has become clear that epigenetic modifications play an important role in
the regulation of microRNA and that dysregulated expression of microRNA occurs in a
variety of pathologic conditions (36-38). Herein we have shown that the high expression of
miR-203 in RASFs leads to increased secretion of IL-6 and MMP-1, two molecules that are
highly associated with RA pathogenesis and contribute importantly to chronic inflammation
and joint destruction in the disease. Given recent reports of successful approaches to
targeting miRNA in vivo (39-41), our data suggest that miR-203 may be a new therapeutic
target in RA.
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Figure 1.
Increased basal expression of microRNA-203 (miR-203) in synovial fibroblasts from
patients with established rheumatoid arthritis (RA). A, Basal expression of miR-203 in
synovial fibroblasts from normal synovium (NSF), from patients with osteoarthritis (OASF),
from patients with early RA (eRASF), and from patients with RA at a later stage of the
disease (RASF). Bars show the mean. P values were determined by Mann-Whitney test with
Bonferroni correction. B, Basal expression of miR-203 in OA synovial tissue (n = 6) and RA
synovial tissue (n = 5). Data are presented as box plots, where the boxes represent the 25th
to 75th percentiles, the lines within the boxes represent the median, and the lines outside the
boxes represent the minimum and maximum values.
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Figure 2.
Epigenetic regulation of the expression of miR-203. A, Changes in the expression of
miR-203 by RASFs (n = 6) after stimulation for 12 hours with interleukin-1 (IL-1), tumor
necrosis factor (TNF), and lipopolysaccharide (LPS). Expression was measured by real-time
polymerase chain reaction (PCR). Values are the mean ± SEM. B, CpG content (CG%) in
2,000 bp of miR-203 promoter and let-7a promoter. Gray shading shows particularly high
density of CpG sites in the 680 bp adjacent to the miR-203 gene transcription initiation site
(arrows). C, Changes in the expression of let-7a and miR-203 in healthy synovial
fibroblasts (n = 2) after incubation for 1 week with 1 μM 5-azacytidine (5-aza). Expression
was measured by real-time PCR. See Figure 1 for other definitions.
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Figure 3.
Increased levels of matrix metalloproteinase 1 (MMP-1) associated with increased
expression of microRNA-203 (miR-203) in rheumatoid arthritis synovial fibroblasts
(RASFs). A, RASFs were transfected with miR-203 precursor (pre–miR-203) or control pre-
miR. MMP-1 transcripts were measured by real-time polymerase chain reaction after 24, 48,
and 72 hours. Bars show the mean. P values (versus levels in control pre-miR–transfected
cells [reference; set at 1]) were determined by Wilcoxon’s matched pairs test. B, MMP-1
levels in the supernatants of control pre-miR–transfected and pre–miR-203–transfected
RASFs (both n = 5) were measured by enzyme-linked immunosorbent assay after 72 hours.
Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the
lines within the boxes represent the median, and the lines outside the boxes represent the
minimum and maximum values. P value was determined by Wilcoxon’s matched pairs test.
C, MMP-3, MMP-9, and MMP-13 transcripts were measured 48 and 72 hours after
transfection of RASFs with control pre-miR or pre–miR-203. Levels in control pre-miR–
transfected cells (set at 1) were used as the reference.
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Figure 4.
Increased levels of interleukin-6 (IL-6) associated with increased expression of miR-203 in
RASFs. A, RASFs were transfected with pre–miR-203 or control pre-miR. IL-6 transcripts
were measured by real-time polymerase chain reaction after 12, 24, 48, and 72 hours. Bars
show the mean. P values (versus levels in control pre-miR–transfected cells [reference; set at
1]) were determined by Wilcoxon’s matched pairs test. B, IL-6 levels in the supernatants of
control pre-miR–transfected and pre–miR-203–transfected RASFs (both n = 9) were
measured by enzyme-linked immunosorbent assay (ELISA) after 48 hours. Data are
presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines
within the boxes represent the median, and the lines outside the boxes represent the
minimum and maximum values. P value was determined by Wilcoxon’s matched pairs test.
C, The correlation between basal levels of IL-6 and basal levels of miR-203 in synovial
fibroblasts was determined by Spearman’s rank correlation test. D, RASFs were transfected
with control pre-miR or pre–miR-203. Twelve hours after transfection, RASFs were left
without further treatment or were treated for a further 12 hours with the IκB kinase 2
inhibitor SC-514. IL-6 levels in the supernatants (n = 6) were measured by ELISA. Values
are the mean ± SEM. P values were determined by Wilcoxon’s matched pairs test. See
Figure 3 for other definitions.
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Figure 5.
Expression of predicted targets of miR-203 after miR-203 overexpression. RASFs were
transfected with pre–miR-203 or control pre-miR. Transcripts of the genes for nuclear factor
of κ light polypeptide gene enhancer in B cells inhibitor (NFkBia), NF-κB p100, NF-κB–
repressing factor (NkRF), tumor necrosis factor α–induced protein 3 (TNFAIP3), Tax1-
binding protein 1 (TaxBP1), ring finger protein 11 (RNF11), suppressor of cytokine
signaling 3 (SOCS-3), SOCS-6, and methyl CpG binding protein 2 (MECP2) were measured
by real-time polymerase chain reaction after 12, 24, 48, and 72 hours. Levels in control pre-
miR–transfected cells (set at 1) were used as the reference. Bars show the mean. See Figure
3 for other definitions.
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Table 1
Basal levels of microRNA-203 (miR-203) in patients with established rheumatoid arthritis, by treatment
Patient/treatment miR-203, ΔCt
1/leflunomide 9.23
2/methotrexate 12.47
3/methotrexate 10.77
4/methotrexate, prednisone 11.09
5/methotrexate, prednisone 10.53
6/methotrexate, deflazacort 12.29
7/leflunomide, prednisone 11.32
8/tocilizumab 10.38
9/leflunomide, methotrexate, adalimumab,
 deflazacort
11.09
10/none 12.34
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